Providers must clarify incorrect info

Share this article:
Accredited providers will be responsible for offering corrective information to learners, faculty and planners if an activity is found to break rules for independence, freedom from commercial bias or content validation, ACCME said.
Providers will determine how to communicate the information and are under no obligation to say that they are doing so because the activity was found noncompliant. Nor will learner credits be revoked.
“The idea is not to make the learners further victim of biased information,” Dr. Murray Kopelow, ACCME chief executive, told MM&M. Besides, he pointed out, the AMA PRA Category 1 credit system is the sole purview of the American Medical Association.
Providers must also issue a corrective statement to the ACCME, including a report of the information transmitted.
The policy change was adopted at the council's November 2010 board meeting and will be implemented going forward, following internal review and a public comment period that ended in September.
It's the second refinement ACCME has made this year to the Complaints and Inquiries process, which it uses to investigate criticisms lodged against activities. In July, the council decided, based on stakeholder feedback, that accredited med ed providers who break the rules should not be identified, unless changes in their accreditation status occur. The community had voted overwhelmingly in favor of discretion during the adjudication process.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?